ReviewAntibiotics (Basel, Switzerland)2014
The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia.
Review in Antibiotics (Basel, Switzerland), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 56 citations in OpenAlex.
- Therapeutic Failure in Invasive Fungal Infections: Beyond Antifungal Resistance-A Narrative Review.Journal of fungi (Basel, Switzerland) · 2026Review
- Evaluation of Quantitative Differences of Classic Methods, Fungal Biomarkers, and T2Candida for Assessing the Central Venous Catheter Origin of Candidemia.Open forum infectious diseases · 2026Article
- Article
- Graphene Oxide Composites with Ultrahigh-Molecular-Weight Polyethylene for Innovative Prostheses for Arthroplasty.ACS applied bio materials · 2026Article
- Temporal and anatomic determinants of central-line-associated bloodstream infection risk in a tertiary PICU: a 3-year time-to-event and competing-risk analysis.Frontiers in pediatrics · 2026Article
- Amphibian-Derived Peptide Analog TB_KKG6K: A Powerful Drug Candidate AgainstJournal of fungi (Basel, Switzerland) · 2025Article
- Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin againstAntimicrobial agents and chemotherapy · 2025Article
- Improved Sixty-Day Mortality in Candidemia with Antifungal Treatment Within 72 Hours of Fever Onset: A Single-Center Retrospective Study in Rural Japan.Infectious disease reports · 2025Article
- Biofilm formation and drug susceptibility of biofilmIranian journal of microbiology · 2024Article
- Molecular Determinants Involved in Candida albicans Biofilm Formation and Regulation.Molecular biotechnology · 2024Review
- Amphotericin B in the Era of New Antifungals: Where Will It Stand?Journal of fungi (Basel, Switzerland) · 2024Review
- Antifungal therapy ofBiofilm · 2023Article
- Microbial Biofilms: Applications, Clinical Consequences, and Alternative Therapies.Microorganisms · 2023Review
- Contribution ofInfection and drug resistance · 2023Article
- Biofilm: The invisible culprit in catheter-induced candidemia.AIMS microbiology · 2023Review
- Impaired amino acid uptake leads to global metabolic imbalance of Candida albicans biofilms.NPJ biofilms and microbiomes · 2022Article
- Prevention and Eradication of Biofilm by Dendrimers: A Possibility Still Little Explored.Pharmaceutics · 2022Review
- Polymicrobial Biofilm Dynamics of Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2022Article
- Nanotechnology in combating biofilm: A smart and promising therapeutic strategy.Frontiers in microbiology · 2022Review
- Eradication ofJournal of fungi (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Catheter-related bloodstream infection (C-RBSI) is one of the most frequent nosocomial infections. It is associated with high rates of morbidity and mortality. Candida spp. is the third most common cause of C-RBSI after coagulase-negative staphylococci and Staphylococcus aureus and is responsible for approximately 8% of episodes. The main cause of catheter-related candidemia is the ability of some Candida strains-mainly C. albicans and C. parapsilosis-to produce biofilms. Many in vitro and in vivo models have been designed to assess the activity of antifungal drugs against Candida biofilms. Echinocandins have proven to be the most active antifungal drugs. Potential options in situations where the catheter cannot be removed include the combination of systemic and lock antifungal therapy. However, well-designed and -executed clinical trials must be performed before firm recommendations can be issued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.